Oral LHRH antagonists for the treatment of prostate cancer: an update

Some time ago we noted that there were three oral (as opposed to injectable) LHRH antagonists in development for the treatment of prostate cancer, i.e., drugs like degarelix (Firmagon) that could be given by mouth as opposed to needing to be injected. … READ MORE …

New, oral LHRH antagonists in treatment of prostate cancer?

At least three new LHRH receptor antagonists — i.e., drugs similar to degarelix (Firmagon) — are in development at the present time: elagolix, relugolix, and ASP-1707. However, unlike degarelix, all three are agents that would act as oral drugs as opposed to drugs one has to be given as long-term injections. … READ MORE …